Lung Therapeutics, Inc. Doses First Patient in Phase 1 Clinical Trial of LTI-01 in Australia and New Zealand

March 15, 2017

LTI-01 addresses unmet needs in a $600+ million global market. Intended to replace costly surgery and ineffective off-label treatments of fibrosis, the drug can provide safer and more cost-effective therapeutic options for CPE/empyema patients and healthcare providers worldwide. READ FULL ARTICLE...
Read more...

Five of Biotech Showcase’s Most Interesting Startups

January 13, 2016

Austin startup Lung Therapeutics is developing drugs to treat three indications: Pleural effusion (fluid buildup in the lungs), acute lung injury and idiopathic pulmonary fibrosis. by Meghana Keshavan MEDCITY NEWS READ FULL ARTICLE...
Read more...

NIH Grant to Advance Lung Therapeutics’ Empyema Drug Therapy

November 3, 2015

$1.69 million award will go to develop LTI-01 for treatment of pleural effusion with loculation. The National Institutes of Health (NIH) will support research conducted by Dr. Steven Idell, MD, PhD, who serves as UT Health Northeast investigator and chief scientific officer of the pharmaceutical company Lung Therapeutics, Inc. by Leonor Mateus Ferreira LUNG DISEASE...
Read more...

Austin Drug Developer Gets $1.7M NIH Grant

October 27, 2015

Lung Therapeutics, Inc., an Austin-based pharmaceutical startup, has $1.69 million more to pump in the development of a drug that could help people afflicted with pneumonia. AUSTIN BUSINESS JOURNAL READ FULL ARTICLE...
Read more...

Lung Therapeutics, Inc. Chief Scientific Officer Dr. Steven Idell Receives NIH Grant for Phase 1A/1B Clinical Trial of Drug Candidate LTI-01

October 27, 2015

European Orphan Drug Designation gives Lung Therapeutics 10 years of market exclusivity in Europe for LTI-01 in the treatment of empyema, a complication of pneumonia. AUSTIN and TYLER, TX — October 27, 2015 —  Lung Therapeutics, Inc., a pharmaceutical company focused on niche, orphan drug indications addressing unmet therapeutic needs in lung injury and disease,...
Read more...

Emerging Company Profile: Effusion Dissolution

March 30, 2015

Lung Therapeutics, Inc. is developing therapies that prevent or resolve fibrosis to treat orphan lung diseases. Lead product LTI-01 is a formulation of a fibrinolytic enzyme in preclinical development to prevent and clear loculated pleural effusion without resorting to surgery. by Emily Cukier-Meisner, Senior Writer BIOCENTURY ON BUSINESS READ FULL ARTICLE...
Read more...

Orphan Drug Status Granted to Lung Therapeutics Drug by the European Commission

January 26, 2015

The European Commission (EC) has awarded orphan medicinal product designation to Austin-based pharmaceutical company Lung Therapeutics, Inc.’s LTI-01 for the treatment of empyema as a complication from pneumonia. by Leonor Mateus Ferreira BIONEWS TEXAS READ FULL ARTICLE...
Read more...

Lung Therapeutics, Inc. Granted Orphan Drug Designation in the European Union for LTI-01

January 13, 2015

European Orphan Drug Designation gives Lung Therapeutics 10 years of market exclusivity in Europe for LTI-01 in the treatment of empyema, a complication of pneumonia. AUSTIN, TX — January 13, 2015 —  Lung Therapeutics, Inc., a pharmaceutical company focused on niche, orphan drug indications addressing unmet therapeutic needs in lung injury and disease, announced that...
Read more...

FDA Move Opens Funding, Market Assistance for Lung Therapeutics

December 2, 2014

Lung Therapeutics, Inc. (LTI), an Austin-based pharmaceutical startup, will get special considerations from the U.S. Food and Drug Administration to help it develop an injectable drug treatment for a common complication of pneumonia. by Chad Swiatecki, Staff Writer AUSTIN BUSINESS JOURNAL READ FULL ARTICLE...
Read more...

Lung Therapeutics, Inc. Receives FDA Orphan Drug Designation for Lead Drug Candidate LTI-01

December 2, 2014

FDA Orphan Drug Designation gives Lung Therapeutics a seven-year US market exclusivity for LTI-01 in the treatment of empyema, typically a complication of pneumonia. LTI-01 is designed to reduce fibrinous scars in the lung cavity to allow fluid drainage without the need for surgery. AUSTIN, TX — December 2, 2014 —  Lung Therapeutics, Inc., a...
Read more...

Company Address

1515 S. Capital of Texas Highway

Suite 402

Austin, Texas 78746

Phone: +1 512.872.7527

Email: info@lungtx.com

Media Contact

Sandra Oak

Nsight Public Relations

Phone: +1 321.591.1508

Email: soak@nsightpr.com